Ladakamycin en es it fr

Ladakamycin Brand names, Ladakamycin Analogs

Ladakamycin Brand Names Mixture

  • No information avaliable

Ladakamycin Chemical_Formula


Ladakamycin RX_link

Ladakamycin fda sheet

Ladakamycin FDA

Ladakamycin msds (material safety sheet)

Ladakamycin MSDS

Ladakamycin Synthesis Reference

No information avaliable

Ladakamycin Molecular Weight

244.205 g/mol

Ladakamycin Melting Point

229 oC

Ladakamycin H2O Solubility

8.9E+004 mg/L

Ladakamycin State


Ladakamycin LogP


Ladakamycin Dosage Forms

Azacitidine for injectable suspension is supplied as a lyophilized powder in 100 mg single-use vials packaged in cartons of 1 vial.

Ladakamycin Indication

For treatment of patients with the following myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia.

Ladakamycin Pharmacology

Azacitidine is believed to exert its antineoplastic effects by causing hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow. The concentration of azacitidine required for maximum inhibition of DNA methylation in vitro does not cause major suppression of DNA synthesis. Hypomethylation may restore normal function to genes that are critical for differentiation and proliferation. The cytotoxic effects of azacitidine cause the death of rapidly dividing cells, including cancer cells that are no longer responsive to normal growth control mechanisms. Non-proliferating cells are relatively insensitive to azacitidine.

Ladakamycin Absorption

Azacitidine is rapidly absorbed after subcutaneous administration. The bioavailability of subcutaneous azacitidine relative to IV azacitidine is approximately 89%, based on area under the curve.

Ladakamycin side effects and Toxicity

One case of overdose with azacitidine was reported during clinical trials. A patient experienced diarrhea, nausea, and vomiting after receiving a single IV dose of approximately 290 mg/m2, almost 4 times the recommended starting dose.

Ladakamycin Patient Information

Ladakamycin Organisms Affected

Humans and other mammals